Xencor (XNCR) Net Income towards Common Stockholders (2013 - 2026)
Xencor (XNCR) posted quarterly Net Income towards Common Stockholders of -$128.9 million for Q1 2026, down 164.95% year-over-year from $198.5 million in Q1 2025, and down 1838.01% quarter-over-quarter from -$6.7 million in Q4 2025.
Powered by 
Analysis
Xencor (XNCR) Net Income towards Common Stockholders (2013 - 2026) Analysis & Trends
Xencor (XNCR) has reported Net Income towards Common Stockholders for 14 consecutive years, with -$128.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 164.95% year-over-year to -$128.9 million; the TTM figure through Mar 2026 stood at -$172.4 million (up 18.31% YoY), while the FY2025 annual figure was -$92.1 million, up 61.05% from the prior year.
- Net Income towards Common Stockholders declined to -$128.9 million in Q1 2026 per XNCR's latest filing, from -$6.7 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $23.6 million in Q1 2022 and bottomed at -$128.9 million in Q1 2026.
- Historically, Net Income towards Common Stockholders has averaged -$40.8 million across 5 years, with a median of -$34.0 million in 2022.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders soared 1048.69% — and 2023, when it slumped 348.24%.
- Xencor's Net Income towards Common Stockholders stood at -$12.0 million in 2022, then sank by 118.49% to -$26.3 million in 2023, then sank by 75.6% to -$46.2 million in 2024, then soared by 85.6% to -$6.7 million in 2025, then plunged by 1838.01% to -$128.9 million in 2026.
- Business Quant data shows XNCR's Net Income towards Common Stockholders at -$128.9 million in Q1 2026, -$6.7 million in Q4 2025, and -$6.0 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Xencor | 2.01 Bn | 1.64 Bn | - | -21.72 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -21.72 Mn |
| Mar 31, 2026 | -128.94 Mn |
| Dec 31, 2025 | -6.65 Mn |
| Sep 30, 2025 | -6.03 Mn |
| Jun 30, 2025 | -30.78 Mn |
| Mar 31, 2025 | -48.67 Mn |
| Dec 31, 2024 | -46.20 Mn |
| Sep 30, 2024 | -47.44 Mn |
| Jun 30, 2024 | -68.78 Mn |
| Mar 31, 2024 | -74.12 Mn |
| Dec 31, 2023 | -26.31 Mn |
| Sep 30, 2023 | -24.27 Mn |
| Jun 30, 2023 | -26.00 Mn |
| Mar 31, 2023 | -57.85 Mn |
| Dec 31, 2022 | -12.06 Mn |
| Sep 30, 2022 | -32.76 Mn |
| Jun 30, 2022 | -33.98 Mn |
| Mar 31, 2022 | 23.59 Mn |
| Dec 31, 2021 | 73.06 Mn |
| Sep 30, 2021 | -40.19 Mn |